Matrix metalloproteinase inhibitor - Quick-Med Technologies
Latest Information Update: 20 Sep 2010
At a glance
- Originator Quick-Med Technologies
- Mechanism of Action Matrix metalloproteinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Clinical Phase Unknown Rosacea